Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Mechanism Difference: Tirzepatide (Zepbound/Mounjaro): Dual GIP/GLP-1 receptor agonist Semaglutide (Wegovy/Ozempic): GLP-1 receptor agonist only Published Clinical Trial Data (Separate Studies): Tirzepatide (SURMOUNT-1): 16.0% to 22.5% mean weight loss at 72 weeks depending on dose Semaglutide (STEP trials): Approximately 15% mean weight loss at 68 weeks These trials were conducted separately with different patient populations and protocols
United States (U.S.) Duty-Included Shipping For orders shipping to the United States, required U.S
He truly loves what he does and makes sure you are comfortable no matter what service you are getting done
confirm live status before contacting a site
Mild nausea is common during dose escalation but usually improves within weeks
